Nuvaring

NuvaRing is a combined hormonal contraceptive in the form of a flexible, transparent vaginal ring. It releases a low, steady dose of two synthetic hormones, etonogestrel and ethinylestradiol, directly into the vaginal mucosa, providing highly effective pregnancy prevention over a three-week period.

How NuvaRing Works

Unlike oral contraceptives, which must pass through the digestive system, NuvaRing delivers hormones locally through the vaginal wall directly into the bloodstream. This route bypasses first-pass hepatic metabolism, meaning the body requires lower hormone doses to achieve the same contraceptive effect. The ring releases approximately 0.12mg of etonogestrel and 0.015mg of ethinylestradiol per day, maintaining stable plasma hormone levels throughout the three-week wear period.

Etonogestrel, a third-generation progestogen, primarily suppresses ovulation by inhibiting the LH surge. Ethinylestradiol reinforces this effect and also stabilises the endometrial lining, reducing breakthrough bleeding.

Insertion and Use

NuvaRing is inserted into the vagina at the beginning of the menstrual cycle and left in place for exactly three weeks. The user then removes the ring and observes a seven-day ring-free interval, during which a withdrawal bleed typically occurs. A new ring is then inserted to begin the next cycle. The ring does not need to be positioned with medical precision; it simply needs to sit comfortably within the vaginal canal. Most users find it undetectable during everyday activities and intercourse.

If the ring is accidentally expelled or left out for more than three hours, contraceptive efficacy may be reduced, and additional precautions should be used for seven days.

Suitability and Benefits

NuvaRing suits women who prefer a monthly rather than daily regimen and those who find daily pill-taking difficult to maintain. Because hormones are delivered locally, many users experience fewer oestrogen-related systemic side effects compared with oral contraceptives. The method is fully reversible, with fertility typically returning promptly after discontinuation. Like all combined hormonal contraceptives, NuvaRing does not protect against sexually transmitted infections.

Inserting NuvaRing

Insert NuvaRing on the first day of your period for immediate contraceptive protection. Wash your hands, compress the ring between thumb and forefinger, and gently guide it into the vagina as far as comfortable. The exact position is not critical, comfort is the guide. The ring should not be felt once correctly positioned.

Wearing and Removing the Ring

Leave NuvaRing in place for exactly 21 days. To remove, hook your index finger under the ring and pull it out gently. Dispose of it in the provided foil pouch, do not flush. Allow a seven-day ring-free interval before inserting a new ring, during which a withdrawal bleed usually occurs. The ring can remain in place during intercourse. If removed for up to three hours, contraceptive protection is maintained, but use condoms if it is out for longer until the ring has been back in place for seven consecutive days.

One NuvaRing is used per 28-day cycle: three weeks inserted, followed by one ring-free week. Each ring delivers 0.12mg etonogestrel and 0.015mg ethinylestradiol daily. Only one ring is used at a time.

No dose adjustment is required based on body weight or age within the licensed age range. NuvaRing is not indicated in women aged under 18 or post-menopause.

If you forget to insert a new ring after the ring-free week and more than 24 hours have passed, insert a new ring as soon as you remember and use condoms for seven days. If the ring has been out mid-cycle for more than three hours, reinsert it or insert a new ring and use additional contraception for seven days.

NuvaRing should be stored at room temperature (below 30°C) once dispensed. If kept refrigerated (2-8°C) it can be stored until the expiry date on the pack.

Common Side Effects

The following side effects are reported by a notable proportion of NuvaRing users and are generally mild:

• Headache and migraine
• Nausea, particularly during the first one to two cycles
• Vaginal irritation, discomfort, or increased vaginal discharge
• Breast tenderness or swelling
• Mood changes, including low mood or reduced libido
• Intermenstrual spotting, especially in the first few months
• Device-related discomfort or awareness of the ring in the vagina

Serious Side Effects

Although rare, the following serious adverse effects require prompt medical attention:

• Venous thromboembolism (VTE): Deep vein thrombosis or pulmonary embolism, seek emergency help if you experience sudden leg pain, swelling, chest pain, or breathlessness
• Arterial thrombosis: Stroke or myocardial infarction, presenting as severe headache, visual disturbance, facial drooping, arm weakness, or chest pain
• Severe hypertension: Blood pressure should be monitored regularly during use
• Liver tumours: Rare but reported with combined hormonal contraceptives, upper abdominal pain may indicate this
• Cervical cancer: Long-term use may slightly increase risk; regular cervical screening is important

Thrombosis and Cardiovascular Risk

NuvaRing carries the same risk of venous thromboembolism as combined oral contraceptives. The absolute risk remains low but is higher than in non-users. Women with a personal or family history of VTE, known thrombophilias, obesity, or prolonged immobilisation are at increased risk. Inform your prescriber of all relevant risk factors before starting. Discontinue immediately and seek medical review if symptoms of thrombosis appear.

Women who smoke and are aged over 35 should not use combined hormonal contraceptives due to the synergistic cardiovascular risk. Blood pressure should be measured before starting NuvaRing and monitored during use.

Interactions and Reduced Efficacy

Several medicines may reduce NuvaRing's effectiveness, including enzyme-inducing drugs (rifampicin, carbamazepine, phenytoin, St John's Wort). Inform your doctor or pharmacist of all medications and supplements you are taking. Additional contraception or an alternative method may be necessary.

NuvaRing does not protect against HIV or other sexually transmitted infections. Women at risk of STIs should use condoms in addition to NuvaRing.

If you experience migraine with aura for the first time while using NuvaRing, discontinue immediately and seek medical review, as this is associated with increased stroke risk. Regular six-monthly check-ups including blood pressure measurement are recommended for all users.

NuvaRing must not be used in women with any of the following:

• Current or history of venous thromboembolism (DVT or pulmonary embolism)
• Known thrombophilia (e.g. Factor V Leiden, antiphospholipid syndrome)
• Current or history of arterial thrombosis (stroke, TIA, myocardial infarction)
• Uncontrolled or severe hypertension
• Migraine with aura
• Diabetes mellitus with vascular complications
• Severe or active liver disease, or liver tumours
• Hormone-sensitive cancers, including breast and endometrial cancer
• Unexplained vaginal bleeding
• Pregnancy or breastfeeding (especially in the first six weeks post-partum)
• Hypersensitivity to etonogestrel, ethinylestradiol, or any excipient